Clinical Trials Directory

Trials / Unknown

UnknownNCT04943523

Krill Oil and Muscle Weakness in Type 2 Diabetes

Effects of Krill Oil Supplementation on Muscle Mass and Function in People With Muscle Weakness and Type 2 Diabetes

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Dasman Diabetes Institute · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. The prevalence of sarcopenia is unclear but is estimated to be between 4.6 and 7.9% and the loss of skeletal muscle mass and function is accelerated in people with type 2 diabetes. With the percentage of older people and the percentage of people with type 2 diabetes predicted to rise in coming years it is crucial to develop therapies to increase muscle mass and function. Alterations in nutrition have also been suggested to be of therapeutic use in sarcopenia. Epidemiological data showed that the consumption of fatty fish is positively associated with muscle function in older population, indicating a potential role for long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in increasing muscle mass and function in older people. The aim of the current study, therefore, is to determine the effects of krill oil supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKrill OilKrill oil supplements 4g/day
DIETARY_SUPPLEMENTVegetable Oilvegetable oil supplements 4g/day

Timeline

Start date
2022-05-01
Primary completion
2024-08-01
Completion
2024-08-01
First posted
2021-06-29
Last updated
2023-09-13

Locations

1 site across 1 country: Kuwait

Source: ClinicalTrials.gov record NCT04943523. Inclusion in this directory is not an endorsement.